Probiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage

• Published in: PloS one Vol. 13; no. 8; p. e0202901
• Main Authors: García-Arroyo, Fernando E, Gonzaga, Guillermo, Muñoz-Jiménez, Itzel, Blas-Marron, Mónica G, Silverio, Octaviano, Tapia, Edilia, Soto, Virgilia, Ranganathan, Natarajan, Ranganathan, Pari, Vyas, Usha, Irvin, Anthony, Ir, Diana, Robertson, Charles E, Frank, Daniel N, Johnson, Richard J, Sánchez-Lozada, L Gabriela
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 24-08-2018; Public Library of Science (PLoS)
• Subjects: Acids; Animals; Biology and Life Sciences; Blood pressure; Care and treatment; Complications and side effects; Control; Cytoprotection - drug effects; Diet; Dietary Supplements; Dose-Response Relationship, Drug; Excretion; Fecal microflora; Health aspects; Hypertension; Hyperuricemia; Hyperuricemia - chemically induced; Hyperuricemia - metabolism; Hyperuricemia - pathology; Hyperuricemia - prevention & control; Infectious diseases; Intestinal microflora; Kidney - drug effects; Kidney - injuries; Kidney - metabolism; Kidney - pathology; Kidney diseases; Laboratory animals; Male; Medicine and Health Sciences; Metabolism; Microbiota; Nephrology; Oxidative stress; Oxidative Stress - drug effects; Oxonic Acid - adverse effects; Physical Sciences; Physiological aspects; Pilot Projects; Prevention; Probiotics; Probiotics - pharmacology; Rats; Rats, Wistar; Rheumatism; Risk factors; Structure-function relationships; Uric acid; Uric Acid - metabolism; United States > US; Mexico
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0202901

Hyperuricemia is highly prevalent and especially common in subjects with metabolic, cardiovascular and renal diseases. In chronic kidney disease, hyperuricemia is extremely common, and uric acid (UA) excretion relies on gut uricolysis by gut microbiota. Current therapy for lowering serum UA includes drugs that may produce undesired secondary effects. Therefore, this pilot study was designed to evaluate the potential of two probiotic supplements to reduce systemic uric acid concentrations. Secondary objectives were to assess whether the hypouricemic effect related to a therapeutic benefit on the hyperuricemia-induced renal damage and hypertension. Analysis of fecal microbiota was also performed. Groups of 6 rats each were followed for 5 weeks and allocated in the following treatment groups: C = Control; HU-ND = Oxonic acid-induced hyperuricemia (HU) +regular diet; HU-P = HU+placebo; HU-F1 = HU+ probiotics formula 1 and HU-F2 = HU+ probiotics formula 2. We confirmed that oxonic acid-induced hyperuricemia produced hypertension and renal functional and structural changes, along with modest changes in the overall composition of fecal microbiota. Both probiotic-containing diets prevented HU, elevated UA urinary excretion and intrarenal UA accumulation induced by oxonic acid. The hypouricemic effect conferred by probiotic supplementation also prevented the renal changes and hypertension caused by hyperuricemia. However, probiotic treatment did not restore the fecal microbiota. In conclusion, we demonstrated for the first time the ability of probiotics containing uricolytic bacteria to lower serum uric acid in hyperuricemic animals with beneficial consequences on blood pressure and renal disease. As probiotics supplements are innocuous for human health, we recommend clinical studies to test if probiotic supplements could benefit hyperuricemic individuals.